Our top pick for
Merck & Co., Inc is a drug manufacturers-general business based in the US. Merck-and-CoInc shares (MRK) are listed on the NYSE and all prices are listed in US Dollars. Merck-and-CoInc employs 71,000 staff and has a trailing 12-month revenue of around USD$47.3 billion.
|Latest market close||USD$79.83|
|52-week range||USD$63.7645 - USD$89.2225|
|50-day moving average||USD$81.2712|
|200-day moving average||USD$81.0837|
|Wall St. target price||USD$96.53|
|Dividend yield||USD$2.6 (3.06%)|
|Earnings per share (TTM)||USD$4.528|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-4.99%|
|1 month (2020-12-17)||0.01%|
|3 months (2020-10-16)||79.83|
|6 months (2020-07-17)||-0.05%|
|1 year (2020-01-17)||-12.25%|
|2 years (2019-01-17)||5.60%|
|3 years (2018-01-17)||28.70%|
|5 years (2016-01-15)||56.10%|
Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Merck-and-CoInc shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2554. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$19 billion.
The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$47.3 billion|
|Operating margin TTM||32.95%|
|Gross profit TTM||USD$33.7 billion|
|Return on assets TTM||11.26%|
|Return on equity TTM||41.06%|
|Market capitalisation||USD$210 billion|
TTM: trailing 12 months
There are currently 13.6 million Merck-and-CoInc shares held short by investors – that's known as Merck-and-CoInc's "short interest". This figure is 0.9% up from 13.5 million last month.
There are a few different ways that this level of interest in shorting Merck-and-CoInc shares can be evaluated.
Merck-and-CoInc's "short interest ratio" (SIR) is the quantity of Merck-and-CoInc shares currently shorted divided by the average quantity of Merck-and-CoInc shares traded daily (recently around 8.5 million). Merck-and-CoInc's SIR currently stands at 1.59. In other words for every 100,000 Merck-and-CoInc shares traded daily on the market, roughly 1590 shares are currently held short.
However Merck-and-CoInc's short interest can also be evaluated against the total number of Merck-and-CoInc shares, or, against the total number of tradable Merck-and-CoInc shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merck-and-CoInc's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Merck-and-CoInc shares in existence, roughly 10 shares are currently held short) or 0.0054% of the tradable shares (for every 100,000 tradable Merck-and-CoInc shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Merck-and-CoInc.
Find out more about how you can short Merck-and-CoInc stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 01/01/2019) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.55/100
Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.65/100
Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.
|Total ESG score||28.35|
|Total ESG percentile||47.16|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||3|
Dividend payout ratio: 42.98% of net profits
Recently Merck-and-CoInc has paid out, on average, around 42.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.06% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.6 per share.
While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.
Merck-and-CoInc's most recent dividend payout was on 8 January 2021. The latest dividend was paid out to all shareholders who bought their shares by 14 December 2020 (the "ex-dividend date").
Merck-and-CoInc's shares were split on a 2:1 basis on 17 February 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Merck-and-CoInc shares which in turn could have impacted Merck-and-CoInc's share price.
Over the last 12 months, Merck-and-CoInc's shares have ranged in value from as little as $63.7645 up to $89.2225. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4433. This would suggest that Merck-and-CoInc's shares are less volatile than average (for this exchange).
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; FUJIFILM Corporation; Intec Pharma Ltd.; Transcenta Holding Ltd.; and Janux Therapeutics, Inc. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.